Search results for "TUMORI DEL FEGATO"

showing 2 items of 2 documents

EPATOMI MALIGNI DEL BAMBINO

1991

I tumori magli del fegato in età pediatrica sono rappresentati da due forme istologiche differenti: l'Epatoblastoma (EPB) e l'Epatocarcinoma (EPC). Gli Autori esaminano le caratteristiche cliniche, la stadiazione e gli aspetti terapeutici. Vengono altresì presentati i dati della letteratura ed i risultati del Protocollo Italiano di cura di queste neoplasie.

Settore MED/38 - Pediatria Generale E SpecialisticaSettore MED/20 - Chirurgia Pediatrica E InfantileTumori del bambino tumori del fegato epatoblastoma epatocarcinoma
researchProduct

Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

2011

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…

SorafenibNiacinamideMalemedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsPyridinesAntineoplastic AgentsEPATOCARCINOMAlaw.inventionRandomized controlled triallawDrug ToxicityInternal medicinemedicineHumansProspective StudiesHCCProspective cohort studySurvival analysisAgedHCC; sorafenibHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularSorafenibMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryHepatocellular carcinoma sorafenibRegimenTUMORI DEL FEGATOTolerabilityItalyHepatocellular carcinomaDisease ProgressionsorafenibFemaleLiver cancerbusinessmedicine.drug
researchProduct